Why did ONESOURCE.NS stock drop sharply today?

The drop followed Q3 earnings-call concerns and regulatory uncertainty that could delay revenue recognition. Heavy volume of **2,098,263.00** shares amplified the move, signalling broad selling pressure on ONESOURCE.NS stock.

What valuation metrics matter for ONESOURCE.NS stock?

Key metrics are **PE 831.40**, **PB 2.76**, price-to-sales **23.31** and book value per share **INR 518.08**. These show a stretched earnings multiple versus biotech peers and highlight valuation risk for ONESOURCE.NS stock.

What is Meyka AI's forecast for ONESOURCE.NS stock?

Meyka AI's forecast model projects monthly **INR 1225.85**, quarterly **INR 1412.71**, and yearly **INR 1672.24**, implying a 12‑month upside near **42.79%** versus **INR 1171.60**. Forecasts are model-based and not guarantees.

IN Stocks

Down 24.23% ONESOURCE.NS OneSource Pharma NSE intraday 27 Jan 2026: outlook

ByDanny Kontos January 27, 2026

ONESOURCE.NS stock plunged 24.23% intraday to INR 1171.60 on 27 Jan 2026 on the NSE, marking it among the top intraday losers. The drop followed heavy trading with volume at 2,098,263.00 shares versus an average of 173,556.00, lifting relative volume to 4.19. Investors reacted to earnings-call uncertainty and regulatory concerns reported in market notes, driving a sharp gap from the previous close of INR 1546.30. We break down drivers, valuation gaps, technical signals and Meyka AI model forecasts to frame near-term trade and risk views for OneSource Specialty Pharma Ltd. (ONESOURCE.NS).